Pharmacoeconomic analysis of using drugs containing mycophenolic acid in kidney transplant recipients in the context of domestic pharmaceutical market

Authors

  • V. N. Lesovoy
  • N. V. Bezdetko
  • T. I. Yermolenko

DOI:

https://doi.org/10.14739/2409-2932.2015.2.45152

Keywords:

Mycophenolic Acid, Kidney Transplantation, Pharmaceutical Economics

Abstract

Aim. The use of mycophenolic acid (MPA) in patients after kidney transplantation made it possible to achieve significant results in reducing the number of acute rejection of kidney in recipients, and increasing the long-term survival of transplant.

Methods and results. With the aim of evaluation of the clinical and economic feasibility of conversion kidney transplant recipients from EC-MPS to MMF in the setting of Ukrainian pharmaceutical market, pharmacoeconomic cost minimization method has been investigated a coefficient of «missed opportunities» in the conversion to a less expensive therapy has been calculated, and the analysis of the impact on the budget has been performed.

Conclusion. It has been determined, that the results of pharmacoeconomic calculations present the strong evidence of the economic advantage of MMF over EC-MPS and the feasibility of MMF in patients receiving immunosuppressive therapy with MPA. 

References

Domhan S., Muschal S., Schwager C. et al. (2008) Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol. Cancer Ther, 7, 1656-1668

Chen H, Chen B. (2014) Clinical mycophenolic acid monitoring in liver transplant recipients. World J Gastroenterol, 20(31), 10715-10728.

Sollinger H.W., Sundberg A.K., Leverson G. et al. (2010) Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients. Transplantation, 89 (4), 446-451.

Sollinger H. (2004) Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. Transplant Proc., 36, 517S-520S.

Ciancio G., Burke G.W., Gaynor J.J. [et al. (2011) Randomized Trial of Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium in Primary Renal Transplantation With Tacrolimus and Steroid Avoidance: Four-Year Analysis. Transplantation, 91 (11), 214-218

Langone J., Chan L., Bolin P. et al. (2011) Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, doubleblind, randomized study. Transplantation, 91, 470-478.

Ciancio G., Burke G.W., Gaynor J.J. et al. (2008) Randomized Trial of Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium in Primary Renal Transplant Recipients Given Tacrolimus and Daclizumab/Thymoglobulin: One Year Follow-Up. Transplantation, 86, 67–74.

Rascati K.L. (2008) Essentials of pharmacoeconomics – Lippincott Williams & Wilkins, 20. – 310 р.

Heemann U. et all. (2011) Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant., 26, 2099–2106.

Morris P., Knechtle S.J. (2014) Kidney Transplantation - Principles and Practice.  Elsevier Health Sciences  880 p.

How to Cite

1.
Lesovoy VN, Bezdetko NV, Yermolenko TI. Pharmacoeconomic analysis of using drugs containing mycophenolic acid in kidney transplant recipients in the context of domestic pharmaceutical market. Current issues in pharmacy and medicine: science and practice [Internet]. 2015Jul.14 [cited 2024Mar.28];(2). Available from: http://pharmed.zsmu.edu.ua/article/view/45152

Issue

Section

Original research